Sorafenib for Treatment of Hepatocellular Carcinoma: A Systematic Review
- 1.1k Downloads
Sorafenib, a drug that inhibits Raf serine/threonine kinases mediating cell proliferation and receptor tyrosine kinases involved in angiogenesis, is approved for treatment of advanced hepatocellular carcinoma.
To explore the efficacy and safety of sorafenib for treating advanced HCC, and to identify clinical factors that might affect that efficacy and safety.
We conducted a systematic review using the PRISMA guidelines to identify prospective studies on sorafenib used alone or in combination with systemic and/or loco regional anti-tumor therapy for treating advanced HCC.
We identified 21 prospective trials of sorafenib treatment alone (7) or combined with other treatment (14). In randomized, placebo-controlled trials, sorafenib prolonged overall survival by 2.3–2.8 months, extended the time to tumor progression by 1.4–2.7 months, and increased disease control by 11–19 %. OS and DCRs were lowest for studies with the highest percentage of hepatitis B patients. Most studies reported major side effects (diarrhea, fatigue, and hand–foot syndrome) in <15 % of patients, with greater incidence in patients with advanced cirrhosis and those treated with sorafenib in combination with 5-FU drugs.
Treatment with sorafenib results in statistically significant, but clinically modest, improvements in OS, TTP, and DCR. For patients with hepatitis B, response seems to be poorer than for those with hepatitis C. The frequency of hand–foot syndrome seems to be higher when sorafenib is used in advanced cirrhosis and is combined with 5-FU drugs. It is not clear that sorafenib combined with other treatments is more effective than sorafenib alone.
KeywordsSorafenib Hepatocellular carcinoma Cirrhosis Transarterial chemoembolization Systematic review
This work was supported by the Office of Medical Research, Department of Veterans Affairs, and the National Institutes of Health (R01-CA134571).
Conflict of interest
There is no financial or personal interest to report.
- 2.Pons-Renedo F, Llovet JM. Hepatocellular carcinoma: a clinical update. Med Gen Med. 2003;5:11.Google Scholar
- 3.American Cancer Society. Cancer Facts and Figures 2010. Atlanta: American Cancer Society; 2010.Google Scholar
- 7.NHANES III Data. http://www.cdc.gov/NCIDOD/Diseases/hepatitis/c/plan/HCV_infection.html; 2008.
- 29.Massa E, Stadier C, et al. Efficacy, safety and impact on quality of life of a treatment with sorafenib in elderly cancer patients with advanced hepatocellular carcinoma. Result of a phase II study. Ann Oncol. 2009;20:s65.Google Scholar
- 32.Castroagudin JF, Molina E, et al. Short-term efficacy and safety of treatment of advanced hepatocellular carcinoma with sorafenib. J Hepatol. 2008;48:s141–s142.Google Scholar
- 34.Petrini I, Muul LM, et al. A phase II trial of sorafenib in combination with 5-fluorouracil continuous infusion in patients with advanced hepatocellular carcinoma: preliminary data. J Clin Oncol. 2009;27:4592.Google Scholar
- 35.Gianluca D, Muul LM, et al. Prospective phase II study of combination sorafenib plus mitomycin-c in the treatment of advanced hepatocellular carcinoma. Ann Oncol. 2009;20:8.Google Scholar
- 39.Giuliana F, Rosenberg A, et al. Sorafenib plus cisplatin and gemcitabine in the treatment of advanced hepatocellular carcinoma: a phase II study by the Grupo Oncologico Dell’Italia Meridonale (PROT. GOIM 2705). Cancer Treat Rev. 2010;36:S96.Google Scholar
- 40.Erhardt A, Kollings F, et al. First-in-men demonstration of sorafenib plus TACE for the treatment of advanced hepatocellular carcinoma (SOCRATES trial). Hepatology. 2009;50:1080A.Google Scholar
- 41.Reyes DK, Azad N, et al. Phase II trial of sorafenib wit doxirubicin eluting bead-transarterial chemoembolization (DEB–TACE) for patients with hepatocellular carcinoma: interim safety and efficacy analysis. Hepatology. 2009;50:6A–7A.Google Scholar
- 43.Faivre S, Feng L, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of AVE 1642, a human monoclonal antibody inhibiting the insulin-like grouth factor-1 receptor (IGF-1R/CD221), administered as single agent and in combination with sorafinib as first line therapy in patients with advanced hepatocellular carcinoma. Hepatology. 2010;52:S 466A–288.Google Scholar
- 45.Pinter M, Smith W, et al. An interim safety analysis of sorafenib plus transarterial chemoembolization in hepatocellular carcinoma—a phase I/II pilot study (SORATACE-1 trial). Hepatology. 2010;52:1157A–1759.Google Scholar
- 50.Li X, Feng GS, Zheng CS, et al. Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study. World J Gastroenterol. 2003;9:2445–2449.PubMedGoogle Scholar